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Following the coordinated efforts of five established scientific organizations, this report, the sixth of its kind,
describes activity in Europe for the year 2013 in the area of cellular and engineered tissue therapies, excluding
hematopoietic stem cell (HSC) treatments for the reconstitution of hematopoiesis. Three hundred eighteen
teams from 31 countries responded to the cellular and engineered tissue therapy survey; 145 teams from 25
countries reported treating 2187 patients, while a further 173 teams reported no activity. Indications were
musculoskeletal/rheumatological disorders (45%; 89% autologous), cardiovascular disorders (20%; 99% au-
tologous), hematology/oncology, predominantly prevention or treatment of graft versus host disease (GvHD)
and HSC graft enhancement, (19%; <1% autologous), neurological disorders (3%; 100% autologous), gastro-
intestinal disorders (2%; 32% autologous), and other indications (11%; 67% autologous). The majority of
autologous cells (88%) were used to treat musculoskeletal/rheumatological (57%) and cardiovascular (27%)
disorders, whereas allogeneic cells were used mainly for hematology/oncology (64%). The reported cell types
were mesenchymal stem/stromal cells (MSC) (49%), HSC (28%), chondrocytes (11%), dendritic cells (2%),
keratinocytes (1%), and others (9%). In 46% of the grafts, cells were delivered following ex vivo expansion,
sorted in 17% of the reported cases and transduced in only 3%. Thirty three percent of treatments were
delivered intravenously or intra-arterially, and of the remaining 67%, 37% used a membrane/scaffold, 28% a
suspension, and 2% a gel. The data are compared to those previously collected to identify trends in a still
unpredictably evolving field.
Introduction
Cell- and tissue-based therapeutic approaches areprogressively gaining ground in the clinics, in part, due
to renewed interest shown by public bodies, for example,
government-sponsored programs and public charities, to-
gether with increasing attention from private funders.1 In
Europe, the main drivers in this arena have been academic
institutions and small–medium enterprises that have been able
to progressively ‘‘GMPify’’ cellular and tissue-engineered
therapy approaches to make them compliant with the 2007
regulatory framework and the subsequent national and EU-
guidelines.2 This development is still ongoing and it has
been of fundamental importance in allowing an under-
standing of the safety and clinical relevance of cells and
tissues as therapeutic tools. Moreover, it represents a fun-
damental learning phase for process setup, manufacturing
and delivery of cells and tissues from the laboratories to the
patients, thereby creating a basis for individualized thera-
pies and, simultaneously, identifying limitations that need to
be overcome. Mapping this scenario is of the utmost im-
portance for the progression of the field, which currently
involves thousands of patients affected by different condi-
tions and impacts clinical, biomedical, regulatory as well as
commercial stakeholders.
Against a background of innovations in science, together
with the above-mentioned regulatory environment con-
cerning the use of cellular and engineered tissue therapies,
the European sections of the Tissue Engineering and Re-
generative Medicine International Society (TERMIS-EU),
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of the International Society for Cellular Therapy (ISCT), of
the International Federation for Adipose Therapeutics
(IFATS), and of the International Cartilage Repair Society
(ICRS), in a joint initiative with the European group for
Blood and Marrow Transplantation (EBMT), established a
survey of cellular and engineered tissue therapies. Since
2008, the number of patients treated in Europe with cells or
engineered tissues has been collected and sorted by specific
therapeutic indications, cell/tissue and donor types and, to-
gether with the processing and delivery modes, analysed to
describe the evolving situation at the European level.3–7 It is
thanks to the continued efforts of the different working
groups that this yearly collection of data represents a means
of monitoring changes and capturing trends in a complex
and still rather unpredictably developing field.
In this study, we report the results of the sixth survey for
the activity, related to patients treated in 2013. The infor-
mation presented is generally available ahead of published
studies, since safety/efficacy data are not required and is
complementary to that available in public databases (e.g.,
www.clinicaltrials.gov), the survey specifying the number of
treatments effectively conducted opposed to those planned.
Patients and Methods
Definitions
For the purpose of this survey, cellular and engineered
tissue therapy is any clinical treatment based on living cells,
excluding donor lymphocyte infusions and nonmanipulated
hematopoietic cells, for hematological reconstitution.
Data collection and validation
Participating teams were, as in previous years, requested
to report their data for 2013 by indication, cell type and
source, donor type, processing method, and delivery mode.
Some modifications were made to the survey form: dendritic
cells were added to the cell type and source, the delivery
mode was amended (intravenous/intra-arterial [i.v./i.a.] and
intra-organ—either suspension, gel or membrane/scaffold),
and a new question included to identify the number of pa-
tients treated as part of a clinical trial, as individualized/
single cases or as a routine therapy.
The survey followed the traditional principles of the
EBMT transplant activity survey, which concentrates on
numbers of patients with a first cellular therapy. Six hundred
eighty-seven teams known to be actively transplanting in 48
countries (39 European and 9 affiliated countries) were
contacted for the 2013 EBMT survey, to which were added
members of the other participating societies and teams who
had contributed to any earlier survey. The non-European
countries affiliated with the EBMT activity survey are Al-
geria, Iran, Israel, Jordan, Lebanon, Nigeria, Saudi Arabia,
South Africa, and Tunisia. Extended questionnaires, in the
format displayed in Supplementary Table 1 (Supplementary
Data are available online at www.liebertpub.com/tea), were
received in paper form and electronically.
Transplant rates
Transplant rates, defined as the reported numbers of pa-
tients receiving cellular or engineered tissue therapies and
the number of teams reporting treatments per 10 million
inhabitants, were computed for each country, without adjust-
ments for patients who crossed borders or received treatment
in a foreign country. Population numbers were obtained
from the 2013 US census office database (www.census.gov).
Results
Participating teams
Three hundred eighteen teams from 31 countries (28
European, 3 EBMT affiliated countries) responded to the
cellular and engineered tissue therapy survey of patients
treated in 2013. One hundred forty-five teams (25 countries:
23 European, 2 EBMT affiliated—Iran, Israel) reported
performing cellular or tissue-engineered therapies: 142 of
these teams provided detailed information on indication, cell
source and type, donor type, cell/tissue processing, and
delivery mode. A further 173 teams reported no activity.
Teams who reported treating patients for the previous sur-
vey edition (treatments in 2012) and did not respond this
year were directly contacted with repeated personal mes-
sages. Teams that responded with detailed information on
their activity are listed in Appendix 1 in alphabetical order
of country, then city. In addition, their EBMT CIC code (if
applicable), the total number of reported cellular or tissue-
engineered therapies, and the split between allogeneic and
autologous donors is included.
Number of cellular or tissue-engineered therapies
and disease indications
According to the received reports, 2187 patients were
treated with cellular or engineered tissue therapies: data on
six patients were excluded from the analysis due to the ab-
sence of complete information. Of the remaining 2181 pa-
tients, 1552 (71%) were treated with autologous cells and 629
(30%) with allogeneic cells (Table 1). Indications were
musculoskeletal/rheumatological disorders (45%; 89% au-
tologous), cardiovascular disorders (20%; 99% autologous),
hematology/oncology (predominantly prevention or treat-
ment of graft versus host disease [GvHD], and hematopoietic
stem cell [HSC] graft enhancement) (19%; <1% autologous),
neurological disorders (3%; 100% autologous), gastrointes-
tinal disorders (2%; 32% autologous), and other indications
(11%; 67% autologous).
As in the previous year, cartilage and bone repair were
by far the most frequently reported indications among
the musculoskeletal/rheumatological disorders, comprising
almost half of all treatments in this group, followed by re-
constructive surgery/tissue enhancement (21% of treat-
ments). Treatments for decubitus and leg ulcers were the
main reasons for a cellular or engineered tissue therapy
among the cardiovascular disorders, closely followed by
peripheral artery disease, together accounting for 62% of
treatments in this group of indications. The number of pa-
tients treated for neurological and gastrointestinal indica-
tions was fairly small (114) and mostly confined to Crohn’s
disease (gastrointestinal) followed by multiple sclerosis and
amyotrophic lateral sclerosis (neurological). Among the
remaining indications, most patients were treated for skin
reconstruction (burns) or for solid tumor excision (Table 1).
One hundred eighteen patients were reported under mis-
cellaneous, that is, they were treated for indications other
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than those mentioned in the form, for example, for hemor-
rhagic cystitis.
Cell type, source, and donor type
The reported cell types were mesenchymal stem/stromal
cells (MSC) (49%), HSC (28%), chondrocytes (11%),
dendritic cells (2%), keratinocytes (1%), and others (9%).
This year, no treatments were reported using dermal fibro-
blasts. From 1074 MSC-based therapies, 53% were autolo-
gous transplants, and of the 618 HSC treatments, 94% were
autologous transplants (Table 1). Of the remaining cell
sources, all chondrocyte transplants, 93% of dendritic cells,
21% of keratinocytes and 70% of other cell sources, were
autologous.
The majority of autologous cells (88%) were used to treat
musculoskeletal/rheumatological, cardiovascular, or neurolog-
ical indications (57%, 27%, and 4%, respectively). Although
only a small number of patients (67) had neurological disor-
ders, all treatments used autologous cells. The main uses of
allogeneic cells were, as in previous years, for hematology/
oncology (64%) and for musculoskeletal/rheumatological
indications (17%), almost all of which were for cartilage
repair (Fig. 1). The trends for the various therapy areas over
the last 5 years are shown in Figure 2.
In 2013, MSC were mostly obtained from bone marrow
(69%) or adipose tissue (30%). MSC were used mainly for
GvHD (32%) or for two musculoskeletal indications, namely
cartilage repair (24%) and reconstructive surgery/tissue en-
hancement (19%). For the HSC treatments, cells were derived
from peripheral blood (70%) or bone marrow (29%): 61% of
them were used to treat cardiovascular disorders, mainly
periperhal artery disease or decubitus and leg ulcers, and 25%
for musculoskeletal/rheumatological indications, mainly bone
repair. All chondrocyte preparations were for cartilage and
bone repair. Keratinocytes were almost exclusively used for
either skin reconstruction or reconstructive surgery/tissue
enhancement. Only a small number of patients (40) were
treated with dendritic cells, here identified as a cell source for
the first time. These cells were used for solid tumor (29 pa-
tients), arthritis and liver insufficiency. The cell source
‘‘other’’ (i.e., not among those foreseen in the form) was
reported for 183 (8%) patients. The teams also reported the
use of combinational treatments, for example, fat cells aug-
mented with monocytes from peripheral blood cells (in re-
constructive surgery/tissue enhancement or chondrocytes
with allogeneic MSC for cartilage repair). These could not be
consistently captured by the format of the questionnaire and
data display, but are worth being qualitatively mentioned here
since they are in line with recently published trends.8,9 The
use of hybrid products such as these, combining cell types or
combining cells with bone marrow fraction or blood-derived
additives, is clearly on the rise and will need to be monitored
in a revised survey edition in future years.
Cell processing and delivery mode
Of all the grafted products, just under half underwent cell
expansion (46%), 3% (55 patients only) were transduced,
and 17% were sorted (Table 2). Ninety-two percent of
cardiovascular, 53% of musculoskeletal/rheumatological,
and 45% of neurological indications were treated with
nonexpanded cells, while gastrointestinal indications were
mainly treated (60%) with expanded cells. Expanded cells
FIG. 1. Percentage of in-
dications for cellular and en-
gineered tissue therapies in
Europe in 2013, sorted by
donor type. Data used for this
chart were derived from the
extended questionnaire and
the standard European Group
for Blood and Marrow
Transplantation (EBMT)
survey sheet.
FIG. 2. Comparative analysis of indications for cellular and engineered tissue therapies in Europe from 2009 to 2013,
sorted by donor type. Data used for this chart were derived from the current study and four previous reports.3–7
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were also used for 94% of hematology/oncology treatments
and 35% of treatments for skin reconstruction.
Cell sorting was applied predominantly for musculo-
skeletal/rheumatological (69% of all sorted cells) and car-
diovascular indications (18% of all sorted cells). 264
patients with musculoskeletal/rheumatological indications
(27% of all patients in this group), of whom 201 were
treated for cartilage repair, received treatment with sorted
cells as did 69 patients with cardiovascular indications (16%
of all patients in this group).
Of the 39% of cells reported to be processed using an
automated device, most were used to treat musculoskeletal/
rheumatological (50%) and cardiovascular (39%) indications.
Thirty-three percent of the cells were delivered intrave-
nously or intra-arterially. Of the remaining 67% (intra-organ
delivery), 37% used a membrane/scaffold, 28% a suspension,
and 2% a gel (Table 3). Intravenous (i.v.) or intra-arterial (i.a.)
delivery was reported for all hematology/oncology treatments
(56% of all i.v. and i.a. treatments) and for 74% of gastroin-
testinal indications. Eighty-five percent of treatments deliv-
ered through a gel were for musculoskeletal/rheumatological
indications (for either bone and cartilage repair or scleroder-
ma). The use of a suspension for cell delivery was reported
mainly for musculoskeletal/rheumatological (55%) and car-
diovascular (28%) indications, while the use of a membrane/
scaffold was split between musculoskeletal/rheumatological
Table 2. Number of Reported Cellular and Engineered Tissue Therapy
Treatments in Europe in 2013 Sorted by Processing Mode
Indications
Cell processing
Nonexp. Expanded Untransduced Transduced Unsorted Sorted Automated Manual
Cardiovascular
Peripheral artery disease 131 131 130 1 119 12
Cardiomyopathy 63 63 7 56 58 5
Heart failure 26 11 14 23 37 37
Myocardial ischemia 41 16 57 45 12 16 41
Decubitus + leg ulcers 129 6 135 135 129 6
Other/unspecified 3 3 3 3
Musculoskeletal/rheumatological
Bone repair (maxillofacial) 75 75 75 75
Bone repair (orthopedics) 48 23 71 56 15 45 26
Osteogenesis imperfecta 1 1 1 1
Cartilage repair
(orthopedics)
112 373 483 2 284 201 87 398
Muscle repair 4 2 6 4 2 2 4
Tendon/ligament 11 40 51 48 3 5 46
Reconstructive surgery/
tissue enhancement
200 6 206 206 154 52
Scleroderma 14 8 22 22 22
Arthritis 62 6 68 27 41 45 23
Other/unspecified 2 4 6 4 2 2 4
Neurological
Multiple sclerosis 4 18 22 21 1 7 15
Amyotrophic lateral
sclerosis
11 9 20 20 11 9
Parkinson’s 3 3 3 3
Peripheral nerve
regeneration (trauma)
4 4 4 4
Other/unspecified 8 10 18 10 8 18
Gastrointestinal
Crohn’s disease 13 20 33 33 33
Liver insufficiency 6 8 10 4 12 2 14
Hematology/oncology
GvHD prevention
or treatment
23 333 353 3 354 2 356
HSC graft enhancement 1 47 48 44 4 1 47
Miscellaneous
Skin reconstruction—burns 42 23 65 65 42 23
Cornea repair 1 1 1 1
Diabetes 6 6 6 6
Solid tumor 38 18 45 11 44 12 11 45
Other 95 23 106 12 106 12 13 105
Total 1175 1006 2126 55 1800 381 825 1356
nonexp, nonexpanded.
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(64%), decubitus and leg ulcers (16%), peripheral artery dis-
ease (11%), and skin reconstruction (burns) (7%).
Treatments for both musculoskeletal/rheumatological and
cardiovascular indications were predominantly delivered
through membrane/scaffold (53% and 52%, respectively) or
suspension (40% and 34%, respectively), with 92% of treat-
ments for skin reconstruction (burns) administered through
membrane/scaffold. No neurological or gastrointestinal indi-
cations were treated using a gel or membrane/scaffold. As this
revised approach to recording the mode of delivery was intro-
duced with this survey, no identification of trends is possible.
Transplant rates and active teams
Reported cellular and engineered tissue therapies were
performed in a limited number of countries and with dif-
ferent intensity. Figure 3 displays the reported transplants
per 10 million inhabitants in the different European and
EBMT-associated countries. The highest transplant rates
(i.e., >40 per 10 million population) were reported in (in
decreasing order) Slovenia, the Netherlands, Italy, Spain,
Belgium, Denmark, the Czech Republic, Norway, and
Switzerland.
The number of teams reporting cellular and tissue-
engineered therapies were also mapped in the different Eu-
ropean and EBMT-associated countries after normalization
to the inhabitant numbers (Fig. 4). The number of reporting
teams per 10 million inhabitants were higher than 4 in
Slovenia, Finland, Belgium, Lithuania, the Netherlands,
Switzerland, and Spain (again in decreasing order).
As of last year, the top 10 countries (out of 31 total)
accounted for 85% of all patients treated.
Table 3. Number of Reported Cellular and Engineered Tissue Therapy
Treatments in Europe in 2013 Sorted by Delivery Mode
Indications
Cell delivery mode
i.v. or i.a
Intra-organ
Suspension Gel Membrane/scaffold
Cardiovascular
Peripheral artery disease 17 26 88
Cardiomyopathy 2 61
Heart failure 3 34
Myocardial ischemia 9 48
Decubitus + leg ulcers 2 133
Other/unspecified 3
Musculoskeletal/rheumatological
Bone repair (maxillofacial) 75
Bone repair (orthopedics) 16 13 42
Osteogenesis imperfect 1
Cartilage repair (orthopedics) 70 166 18 231
Muscle repair 2 4
Tendon/ligament 12 14 25
Reconstructive surgery/tissue enhancement 65 141
Scleroderma 14 8
Arthritis 64 4
Other/unspecified 2 4
Neurological
Multiple sclerosis 18 4
Amyotrophic lateral sclerosis 9 11
Parkinson’s 3
Peripheral nerve regeneration (trauma) 4
Other/unspecified 5 13
Gastrointestinal
Crohn’s disease 25 8
Liver insufficiency 10 4
Hematology/oncology
GvHD prevention or treatment 356
HSC graft enhancement 48
Miscellaneous
Skin reconstruction—burns 5 60
Cornea repair 1
Diabetes 6
Solid tumor 14 36 6
Other 94 17 7
TOTAL 717 608 46 810
i.a, intra-arterial; i.v., intravenous.
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Treatments as part of a clinical trial versus
individualized treatment or routine therapy
With this survey, teams were asked for the first time to
report if patients were treated with cells/engineered tissues
in the context of a clinical trial, as individualized/single
case treatment, or as a routine therapy. Where information
was provided (from 77 teams for 1479 patients, 70% of total
patient number), 46% of patients were treated as rou-
tine therapy, 34% as part of a clinical trial, and 20% as
FIG. 3. Number of cellular
and engineered tissue thera-
pies per 10 million inhabi-
tants reported in Europe in
2013.
FIG. 4. Number of teams
per 10 million inhabitants
reporting cellular and en-
gineered tissue therapies in
Europe in 2013.
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individualized/single cases. Fourteen teams reported treating
675 patients with routine therapies: most (58%) were treated
for musculoskeletal and rheumatological indications (of
which 38% for reconstructive surgery/tissue enhancement
and 50% for cartilage and bone repair), followed by car-
diovascular disorders (32%, of which 60% for decubitus and
leg ulcers and 40% for peripheral artery disease) and 6% for
skin reconstruction following burns. Importantly, 64% of the
treatments reported as ‘‘routine therapy’’ involved the use of
fat- and/or peripheral blood-derived cells. Of the 33 teams
who reported treating 502 patients as part of a clinical trial,
most (59%) were treated for musculoskeletal and rheuma-
tological indications (of which 53% for cartilage repair),
followed by cardiovascular disorders (15%).
Discussion
The data collected for this sixth edition of the cellular and
engineered tissue therapy survey show a modest increase
from the previous year in both the number of reporting
teams and number of patients treated. Since the survey’s
inception, the total number of teams reporting the use of
cellular and engineered tissue therapies has risen from 143
in 2008 to 318 in 2013, with the number of teams reporting
full data rising from 33 in 2008 to 142 in 2013. At the same
time, the total number of patients treated has risen from
1040 in 2008 to 2187 in 2013 (Fig. 5).
We have compared the results obtained from patients
treated in 2013 for specific indications with previous years
and found few significant differences. Although no patients
were treated for bypass graft in 2013, numbers in previous
years were also rather limited (six in 2012 and nine in 2011).
The treatments for patients with heart failure accounted for
9% of all cardiovascular ones, compared to 13% and 17%,
in 2011 and 2012 respectively. This reduction can most
likely be attributed to changes in a limited number of highly
active teams, who did not respond to the survey this time.
As in the previous 2 years, the most used cell source in
2013 was MSC, accounting again for around 50% of the
treatments. The most represented indication for their use
was again GvHD prevention or treatment (15% of all pa-
tients, 333 in all). The use of dermal fibroblasts, employed
almost exclusively for skin reconstruction in previous sur-
veys, was not reported in 2013, indicating that the promise
of bilayered or composite tissue-engineered skin10,11 is still
not reflected in the clinical scenario, which is dominated by
the more conventional use of keratinocytes only. The pri-
mary use of dendritic cells, although for a small number of
patients (29 patients), was related to solid tumor, consistent
with last year’s report, followed by arthritis and liver in-
sufficiency.
Analysis of treatments reported as being carried out in the
context of clinical trials or as a routine therapy was com-
bined with data on associated indications and cells used.
Collectively, such assessments indicate that intra-operative
isolation and use of cells, predominantly in the context of
plastic and reconstructive surgery, are considered a routine
treatment, while procedures employing cell expansion, and
therefore subject to registry under ATMP (Advanced Therapy
Medicinal Product) regulations, are prevalently considered
experimental and thus part of a clinical trial. This trend is
consistent with the fact that ATMPs are only allowed in the
routine clinical practice after having passed cell quality and
efficacy indicator checks, to assure patient, provider, payer,
and policy maker of the safe and effective application of
expensive and personalized treatments. In the specific context
of cell-based cartilage repair, we received reports indicating a
roughly 50-50 split between the use within a clinical trial or
as a routine therapy. Underlying this dichotomy could be the
fact that cartilage cell therapy is part of the reimbursement
system only in some European countries. There is currently
no way to predict the development of reimbursement of cell
therapy for specific indications (e.g., cartilage repair) in in-
dividual EU regions and/or countries. This will have a con-
siderable influence on the field and affect the number of
patients who can be treated in future. Such considerations
indicate that treatment selection and growth, or decline of
treatment choice, is greatly influenced by both political and
local economic factors and related to the social healthcare
systems.
The fact that 66% of patients were treated as either in-
dividualized/single cases or part of routine therapy rather
than as part of a clinical trial indicates that data from clinical
trials represent a subset of those presented here. Never-
theless, analysis of trends from registered clinical studies
(e.g., www.clinicaltrials.gov) and of market data from
companies providing expansion of cells intended for cell
therapy as a service would, although challenging, be highly
informative to complement the yearly survey reports. We
are aware that centers where cellular therapy treatments are
performed likely in significant numbers did not participate
in the survey and a personalized team-hunting strategy (e.g.,
toward previously active or publishing teams) is only par-
tially effective. However, the program is based on answers
supplied on a voluntary basis. The most convincing incen-
tive for active teams to report through our survey will be (1)
FIG. 5. Number of reporting
teams and patients treated using
cellular and engineered tissue
therapies from 2008 to 2013. Data
used for this chart were derived
from the current study and previous
reports.3–7
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to demonstrate the increased recognition of the initiative by
the field and (2) to convey the importance to further develop
it through contributions which are transparently acknowl-
edged without compromising opportunities to publish or
protect clinical data.
Toward the end of 2014, IFATS, the International Fed-
eration for Adipose Therapeutics and Science, became a
supporting society. This addition underlines that the survey
program is continuing to receive growing recognition as a
reference platform for the collection and dissemination of
information that is not available in public databases or sci-
entific publications. ISCT with its other sister societies has
also been increasingly supportive of this European initiative
since its inception. The international nature of most of the
involved societies represents a push for widening the data
collection to other world regions, with global repository of
data, as well as for accelerating the process of data collec-
tion and analysis, toward more timely dissemination of the
information to the Regenerative Medicine and Tissue En-
gineering Community. Indeed a larger collective effort
will be necessary to guarantee that cell-based and tissue-
engineered therapies, despite the challenges to be overcome,
will seriously develop into global opportunities to counter-
act still lethal diseases and unmet clinical needs.
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Appendix:
List of Centers Reporting Use of Cellular
and Engineered Tissue Therapy in Europe in 2013
Format: City, Hospital, Department, Centre Identification
Code (CIC—as used for EBMT teams in the EBMT
standard survey), Physicians (Total treatments: allogeneic/
autologous)
Austria
Krems, University Krems, Regenerative Medicine and
Orthopaedics, S. Nehrer, T. Luksch, P. Holzmann, M.
Gruber (5:0/5)
Vienna, Medical University Hospital, Traumatology, S.
Aldrian, C. Albrecht (4:4/0)
Vienna, Universita¨tsklinik fu¨r Innere Medizin-AKH, CIC
227, H. Greinix, P. Kalhs (1:1/0)
Belarus
Minsk, Belorussian Centre, CIC 591, N. Minakovskaya, Y.
Mareika, A. Alexeichik, O. Aleinikova (15:15/0)
Belgium
Antwerp, Antwerp University Hospital (UZA), CIC 996, W.
Schroyens, Z. Berneman (24:0/24)
Brussels, Military Hospital Queen Astrid, Burn Wound
Centre, G. Verbeken (23:23/0)
Gent, University Hospital, CIC 744, L.A. Noens (1:1/0)
Leuven, University Hospital Gasthuisberg, CIC 209, J.
Maertens, G. Verhoef, M. Renard (1:1/0)
Lie`ge, CHU Liege, Gastrology, E. Louis (10:10/0)
Lie`ge, CHU Liege, Surgery and Transplantation, M.
Meurice (2:2/0)
Lie`ge, University Hospital Sart-Tilman, CIC 726, Y. Be´-
guin, B. de Prijck (22:22/0)
Czech Republic
Prague, Academy of Sciences, Institue of Experimental
Medicine, E. Sykova, S. Konradova, Z. Koci, P. Markova
(27:0/27)
Znojmo, General Hospital Znojmo, Orthopaedics and
Traumatology, R. Hart, P. Smid, M. Komzak (29:0/29)
Denmark
Copenhagen, The Heart Centre Rigshospitalet, Cardiac
Catherization Lab., J. Kastrup (32:0/32)
Copenhagen, University Hospital, Clinical Immunology, A.
Fischer-Nielsen, E. Haastrup, R. Oliveri (6:0/6)
Finland
Helsinki, Children’s Hospital, CIC 219, K.Vettenranta (2:2/0)
Helsinki, Helsinki University Central Hospital, CIC 515, L.
Volin (1:1/0)
Helsinki, HUCH Jorvi Hospital, Orthopaedics, Traumatol-
ogy, T. Paatela (1:0/1)
Turku, University Central Hospital, CIC 225, M. Ita¨la¨-
Remes, M. Kauppila, M. Putkonen, U. Salmenniemi, K.
Remes (10:10/0)
France
Clermont Ferrand, CHU Estaing, Centre de Biotherapie
d’Auvergne, CIC 273, J. Kanold, P. Halle, J.-O. Bay (6:0/6)
Grenoble, CHU de Grenoble (St. Ismier), Unite de Therapie
et d-Ingenierie Cellulaire, A. Moisan, V. Persoons, H.
Egelhofer, O. Detante (14:8/6)
Marseille, Arthosport Centre, Knee Institute, M. Assor
(85:85/0)
Nantes, CHU Nantes, UTCG, Institut de Biologie, CIC 253,
B. Dreno, S. Saı¨agh, S. Bercegeay, D. Heymann, P.
Chevallier (8:6/2)
Paris, Hoˆpital St. Louis, CIC 960, H. Dombret, L. Degos, P.
Rousselot (1:0/1)
Germany
Chemnitz, Klinikum Chemnitz GmbH, Innere Medizin III,
CIC 104, M. Ha¨nel, A. Morgner (7:7/0)
Darmstadt, Agaplesion Elisabethenstift, Klinik fu¨r Orthopa¨-
die, Unfallchirurgie und Sportmedizin, T. Schreyer (0:0/14)
Dinslaken, St. Vinzenz Hospital, Orthopa¨die und Un-
fallchirurgie, W. Zinser, F. Glahn, M. Ru¨ter (36:0/36)
Dresden, Universita¨tsklinikum Carl Gustav Carus, Medizi-
nische Klinik und Poliklinik I, CIC 808, G. Ehninger, M.
Bornha¨user, M. Gahr (22:22/0)
Essen, Universita¨tsklinikum, CIC 259.1, O. Basu, B. Kre-
mens (2:2/0)
Frankfurt, J. W. Goethe Universita¨t, CIC 138, T. Klingebiel,
P. Bader (3:3/0)
Frankfurt, Klinikum Frankfurt Oder, CIC 190, M. Kiehl
(20:20/0)
Halle, BG-Clinic Bergmannstrost, Neurosurgery, H.J. Mei-
sel (13:0/13)
Hannover, Hannover Medical School (MHH), Haematol-
ogy, Haemostasis, Oncology and Stem Cell Transplanta-
tion, CIC 295.1, A. Ganser, J. Krauter (7:1/6)
Hannover, Medizinische Hochschule, CIC 295.2, C. Kratz,
K.W. Sykora (1:1/0)
Homburg/Saar, Universita¨tsklinikum Saarlandes, Experi-
mental Orthopa¨die, H. Madry (8:0/8)
Munich, Klinikum Schwabing, C.M. Wendtner, N. Fischer
(1:1/0)
Munich, Technische Universita¨t Mu¨nchen, Paediatrics, CIC
189, S.Burdach,A.Wawer, I. Teichert- vonLu¨ttichau (2:2/0)
Mu¨nster, Universita¨tklinikum Mu¨nster, CIC 505, H. Ju¨r-
gens, K. Ehlert (1:1/0)
Tu¨bingen, Universita¨tsklinikum, CIC 535, R. Hand-
gretinger, P. Lang (6:3/3)
Wu¨rzburg, Universita¨tsklinikum, CIC 196, P. Schlegel (1:1/0)
Greece
Athens, Academy of Athens Biomedical Research Foundation,
Hellenic Cord Blood Bank, A.C. Papassavas, T.T. Chatzista-
matiou, E. Michalopoulos, C. Stavropoulos-Giokas (15:0/15)
Athens, University of Athens, CIC 604, P. Tsirigotis (1:1/0)
Iran, Islamic Rep.
Shiraz, Nemazee Hospital, Shiraz University Medical Sci-
ences, CIC 188, M. Ramzi (15:0/15)
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Teheran, Shariati Hospital, CIC 633, A. Ghavamzadeh, M.
Jahani (7:7/0)
Israel
Jerusalem, Hadassah University Hospital, CIC 258, R. Or, S.
Slavin (16:16/0)
Petach-Tikva, Children’s Medical Centre, CIC 755, J. Stein
(1:1/0)
Tel Hashomer, Edmond and Lily Safra Children’s Hospital,
Sheba Medical Centre, CIC 572, A. Toren, B. Bielorai, G.
Goldstein, D. Hutt (11:11/0)
Italy
Bologna, 6th div Rizzoli Orth. Institute, RIT- Cell Factory,
L. Roseti, A. Bassi, A. Maso (5:0/5)
Bologna, Hospital St. Orsola, CIC 240, G. Bandini, M.
Cavo, F. Bonifazi (2:0/2)
Bologna, Istituto Ortopedico Rizzoli, 3rd Orthopaedic and
Traumatology Clinic, D. Donati (24:0/24)
Cagliari, Ospedale per le Microcitemie, CIC 811.2, M. Or-
ofino (1:1/0)
Florence, AOU Careggi, BMT Unit, CIC 304, A. Bosi, R.
Saccardi, S. Guidi (4:0/4)
Genova, Istituto Giannina Gaslini, CIC 274, G. Dini, E.
Lanino (1:1/0)
Milan, Istituto Scientifico H.S. Raffaele; Univ. Milan*, Stem
Cells Research Centre; Dept Neurological Sciences*, CIC
813, G. Cossu, F. Ciceri; Y. Torrente* (2:2/0)
Milan, OASI Bio-research Foundation, Ortho. Arthro. Sur-
gery Int., A. Gobbi, D. Lad (47:0/47)
Milan, University of Milan IRCCS, CIC 265, A. Cortelezzi,
E. Tagliaferri (1:1/0)
Monza, Ospedale San Gerardo, CIC 279, A. Rovelli (5:5/0)
Rome, Universita` ‘‘La Sapienza,’’ Experimental Medicine, C.
Marchese, E. Vescarelli, S. Ceccarelli, C. Nodale (21:0/21)
Rome, University Tor Vergata, Reconstructive Surgery, V.
Cervelli, D.J. Bottini, B. De Angelis (473:42/431)
Kazakhstan
Astana, National Research Centre for Oncology and
Transplantation, I. Pivovarova (2:2/0)
Lithuania
Vilnius, Santariskiu Klinikos, CIC 644, L. Griskevicius, I.
Trociukas (11:11/0)
Vilnius, University Children’s Hospital, CIC 508, J. Rascon
(2:1/1)
Netherlands
Amsterdam, Antoni Van Leeuwenhoek Cancer Institute,
CIC 976, S. Rodenhuis, J. Baars (1:0/1)
Amsterdam, VU Medical Centre, Dermatology, S. Gibbs
(4:4/0)
Amsterdam, VU University Medical Centre, CIC 588, E.
Meijer, G.J. Ossenkoppele (6:6/0)
Groningen, University Hospital, CIC 546, G. van Imhoff
(2:2/0)
Leiden, University Hospital, CIC 203, J.H. Veelken, M.
Egeler, P.A. von dem Borne (51:14/37)
Rotterdam, Erasmus Medical University Centre, Orthopae-
dics, S. de Jonge, R.-J. de Vos, J.A.N. Verhaar, J.L. Tol
(12:0/12)
Utrecht, UMC, Orthopaedic Surgery, D. Saris (70:6/64)
Utrecht, UMCU/WKZ, CIC 239.2, M. Bierings, N.M.
Wullffraat (7:7/0)
Utrecht, University Hospital UMCU, CIC 239.1, E. Petersen
(23:23/0)
Norway
Oslo, Oslo University Hospital, Ex vivo cell lab, Dept. Im-
munology, CIC 235, J. Brinchmann (2:0/2)
Tromso, University Hospital North Norway, Orthopaedic
Surgery, G. Knutsen (20:0/20)
Poland
Bydgoszcz, Nicolaus Copernicus University, CIC 764, M.
Wysocki, J. Styczynski, R. Debski (2:2/0)
Cracow, University Children’s Hospital JUMC, Transplan-
tation, CIC 507, J. Gozdzik, W. Czogala, O. Wiecha, S.
Skoczen (3:3/0)
Katowice, Regional Blood Centre, Tissue Bank Department,
H. Bursig, A. Wysocka–Wycisk, P. Sitek, A. Kurzak
(13:0/13)
Lublin, Children’s University Hospital, Haematology, On-
cology, Transplantation, CIC 678, J. Kowalczyk, K.
Drabko, A. Zaucha-Prazmo (1:1/0)
Warsaw, Carolina Medical Centre, R. Smigielski, Z. Pojda
(51:0/51)
Warsaw, Maria Sklodowska-Curie Memorial Cancer Centre
and Institute of Oncology, CIC 800, S. Mazur, Z. Pojda
(27:0/27)
Wroclaw, Lower Silesian Centre, BM Donor Registry, CIC
538, A. Lange (2:0/2)
Portugal
Lisbon, Instituto Portugues de Oncologia, CIC 300, M.
Abecasis (1:1/0)
Russian Federations
Moscow, Federal Research Centre, Pediatric Haematology,
CIC 694, A. Maschan, D. Balachov (22:22/0)
Moscow, Research Haematology Centre of RAS, CIC 930,
V.G. Savtchenko (30:30/0)
Moscow, The Russian Children’s Research Hospital, CIC
411, E. Skorobogatova (3:3/0)
St. Petersburg, Pavlov Medical University, CIC 725, B.V.
Afanasyev, L. Zubarovskaya (32:6/26)
St. Petersburg, Russian Research Institute of Haematology,
BMTU, K.M. Abdulkadyerov, S. Voloshin, A. Kuzyaeva,
I. Iapreeya (9:0/9)
Slovenia
Ljublijana, Educell d.o.o, N. Kregar-Velikonja (3:0/3)
Ljublijana, UMC Ljubljana, Advanced Heart Failure and
Transplantation Centre, B. Vrtovec, G. Poglajen, M. Se-
ver, G. Zemljic (38:0/38)
Ljublijana, University Medical Centre, Haematology, CIC
640, S. Zver, J. Pretnar (30:0/30)
Spain
Barcelona, Hospital Clinic, CIC 214, M. Rovira (6:1/5)
Barcelona, Hospital Quiro´n Teknon, ITRT, Institut de
Tea`pia Regenerativa Tissular, L. Orozco, A. Munar, R.
Soler, F. Soler (116:7/109)
Cadiz, Hospital de Je´rez, CIC 612, S. Garzon (1:1/0)
Cordoba, Hospital Reina Sofia, CIC 238, A. Torres-Gomez,
I. Herrera (26:2/24)
Granada, Hospital Virgen de la Nieves, Serv. Hematologia y
Hemoterapia, CIC 559, M. Jurado Chacon, L. Moratalla
Lo´pez, A. Romero Aguilar, E. Lo´pez Ferna´ndez (1:1/0)
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Leon, Hospital Universitario de Leon, CIC 426, F. Ramos,
N. de las Heras (1:0/1)
Madrid, Clinica CEMTRO, Traumatology and Orthopae-
dics, P. Guille´n-Garcı´a, I. Guillen-Vicente, M. Guillen-
Vicente, S. Arauz de Robles (20:0/20)
Madrid, Fundacion Jimenez Diaz, CIC 309, J.L. Lopez-
Lorenzo (0:0/0)
Madrid, Hospital de la Princesa, CIC 236, A. Figuera, A.
Alegre (3:3/0)
Madrid, Hospital Doce de Octubre, CIC 382, J.J. Lahuerta,
J. de la Serna (3:0/3)
Madrid, Hospital General Universitario Gregorio Maranon,
CIC 819, J.L. Diez-Martin (14:6/8)
Madrid, Hospital Uni Materno Infantil Gregorio Maranon,
CIC 410, C. Belendez (3:0/3)
Madrid, Hospital Universitario Puerta de Hierro, CIC 728,
J.R. Cabrera Martin (8:8/0)
Murcia, Hospital Virgen de la Arrixaca, CIC 323, J.M.
Moraleda (19:0/19)
Palma de Mallorca, USP Clinica Palmaplanas, Stem Centre
SL, S. Dos Anjos Vilaboa (18:0/18)
Pamplona, Clinica Universitaria de Navarra, Cell Therapy
Area, F. Prosper Cardoso, E.J. Andreu, S. Inoges, A.
Lopez (143:7/136)
Pamplona, Clinica Universitaria de Navarra, CIC 737, J.
Rifon (1:1/0)
Pamplona, Hospital de Navarra, CIC 577, E. Olavarria (6:6/0)
Salamanca, Complejo Hospital, CIC 727, D. Caballero
(18:18/0)
Santiago de Compostela, Hospital Clinico Universitario,
CIC 570, J.L. Bello Lopez (2:2/0)
Valencia, Hospital Clinico Universitario, CIC 282, C. So-
lano (1:1/0)
Sweden
Linko¨ping, RIL, University Hospital, CIC 740, A. Sand-
stedt, K. Le Blanc (1:1/0)
Uppsala, University Hospital, CIC 266, K. Carlson (3:3/0)
Switzerland
Basel, University Hospital, Traumatology, M. Jakob, F.
Saxer, M. Mumme (10:0/10)
Geneva, Concept Clinic, K.-U. Schlaudraff (19:0/19)
Lugano, Cardiocentro Ticino, Cardiology, D. Su¨rder, T.
Moccetti, L. Turchetio, M. Radrizzahi (3:0/3)
Zurich, Universita¨ts Kinderklinik, CIC 334, T. Gu¨ngo¨r, F.
Scherer (1:1/0)
Turkey
Adana, Baskent University of Adana, CIC 589, H. Ozdogu,
C. Boga, S. Asma, S. Yuce (2:2/0)
Ankara, Children’s Hospital, B. Tunc, F.M. Azik (1:1/0)
Ankara, Gazi University, Besevler, CIC 169, G. Sucak (1:1/0)
Ankara, University of Ankara, CIC 620, E. Unal, M. Ertem
(5:5/0)
Antalya, Medical Park Antalya Hospital, Pediatric
Stem Cell Transplantation Unit, CIC 911, A. Yesilipek
(5:5/0)
Antalya, Medical Park Hospitals, CIC 919, Y. Koc (1:1/0)
Gaziantep, Gaziantep University Medical School, CIC 402,
M. Pehlivan (3:3/0)
Istanbul, Acibadem University Atakent Hospital, CIC 457,
G. O¨ztu¨rk, F. Erbey (6:6/0)
Istanbul, Cerrahpasa Medical School Istanbul University,
BMT Unit, CIC 761, T. Soysal, S.O. Aydin (1:1/0)
Istanbul, Medical Park Goztepe Hospital, CIC 929, G.
Karasu, O. Dogru (5:5/0)
Istanbul, University of Istanbul, CIC 760, M. Aktan (4:4/0)
Kayseri, Erciyes University Faculty of Medicine, CIC 627.2,
M. Karakukcu (1:1/0)
Kocaeli, Anadolu SaglikMerkezi, CIC 440, Z. Gu¨lbas (2:2/0)
Kozyatagi, Istanbul, Acibadem Kozyatagi Hospital, S. Ratip
(2:2/0)
United Kingdom
Birmingham, Heartlands Hospital, CIC 284, E. Nikolousis,
S. Paneesha (3:3/0)
Birmingham, The Birmingham Children’s Hospital, CIC
781, S. Lawson (8:8/0)
London, Hammersmith Hospitals NHS Trust, CIC 205, J.
Apperley, E. Olavarria, E. Kanfer, A. Rahemtulla, R.
Szydlo (9:9/0)
London, King’s College Hospital, CIC 763, G. Mufti, A.
Pagliuca (1:1/0)
London, London Chest Hospital, Cardiac Research, A.
Mathur, S. Hamshere (3:0/3)
London, St Mary’s Hospital, CIC 866, J. de La Fuente (3:3/0)
London, The Royal Free Hospital, CIC 216, S. Mackinnon
(2:2/0)
Manchester, Royal Children’s Hospital, CIC 521, R. Wynn
(2:2/0)
Manchester, UniversityManchester, CTUnit, R.Guest (7:0/7)
Newcastle upon Tyne, Newcastle-upon-Tyne Hospitals
Foundation Trust, Cellular Therapy Facility, A.M. Dick-
inson, D. Bradley (13:0/13)
Oswestry, RJAH Oswestry Orthopaedic Hospital, P. Harri-
son (29:0/29)
Sheffield, Sheffield Teaching Hospitals NHS Foundation
Trust, Haematology, CIC 778, J. Snowden, A. Vora (7:4/3)
Southampton, CRC Wessex, CIC 704, A. Duncombe, D.
Richardson (2:2/0)
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